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A B S T R A C T
With mass spectrometry imaging (MSI) on tissue microarrays (TMAs) a large number of biomolecules can be
studied for many patients at the same time, making it an attractive tool for biomarker discovery. Here we
investigate whether lymph node metastasis can be predicted from MALDI-MSI data. Measurements are per-
formed on TMAs and then filtered based on spectral intensity and the percentage of tumor cells, after which the
resulting data for 122 patients is further preprocessed. We assume differences between patients with and without
metastasis are expressed in a limited number of features. Two univariate feature selection methods are applied to
reduce the dimensionality of the MALDI-MSI data. The selected features are then used in combination with three
classifiers. The best classification scores are obtained with a decision tree classifier, which classifies about 72% of
patients correctly. Almost all the predictive power comes from a single peak (m/z 718.4). The sensitivity of our
classification approach, which can be generically used to search for biomarkers, is investigated using artificially
modified data.
1. Introduction
With matrix-assisted laser desorption/ionization mass spectrometry
imaging (MALDI-MSI), biomolecules such as proteins, peptides, lipids
and metabolites can be studied directly from tissue sections. Up to
thousands of biomolecular species can be studied simultaneously and
tissues with different disease states can be compared to find differences
in the expression of biomolecules. In this way, biomarkers or biomarker
patterns might be identified that are associated with specific disease
states.
Tissue microarray (TMA) samples consist of arrays of small tissue
pieces from different patients. Using TMAs, one can measure a large
sample set under highly similar experimental conditions, and correlate
the acquired data with clinical data. These properties make TMAs well
suited for biomarker discovery studies. Up to a thousand patient sam-
ples per study can now be analyzed in a MALDI-MSI experiment [1].
There have been several studies that correlate MALDI-MSI data with
cancer progression, see for example [2–8]. So far, many studies that
were successful in the identification of prognostic markers performed
intact protein analysis on fresh frozen tissue sections [3,8]. In [1,9,10]
TMAs with samples from more than 100 patients were used. An im-
portant step in MALDI-MSI classification studies is to select features out
of the high-dimensional data. This can for example be done based on
the score of a univariate statistical test, or by performing Principal
Component Analysis (PCA) and keeping only a few principal compo-
nents. There are several ways to investigate the predictive power of the
selected features. Perhaps the simplest way is to correlate individual
features to the parameter of interest [1,9]. It is also possible to combine
features to increase their predictive power, for example by Hierarchical
Clustering [3,5,8]. Alternatively, a classifier can be trained to predict
the parameter of interest from the features [3,7,11]. Regardless of the
approach chosen, the number of features associated with a prognostic
parameter is typically less than 20. In some studies, an independent
validation of the identified proteins is provided by im-
munohistochemistry.
Head and neck cancer is the world’s sixth most common cancer.
Despite advances in diagnostics and treatment strategies, survival rates
have not improved over the last decades and remain poor, with a 5-year
survival of approximately 50% [12]. The presence of lymph node me-
tastasis at the time of diagnosis is a major predictor for prognosis.
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Unfortunately, in around 30% of patients existing lymph node metas-
tases are not detected with current diagnostic imaging techniques such
as ultrasound-guided fine needle aspiration cytology (FNAC), computed
tomography (CT) and magnetic resonance imaging (MRI).
Tumor profiling with biomarkers has recently shown promising
results [13,14]. A validated gene expression profile accurately pre-
dicted the absence of nodal metastasis in 89% of the patients. However,
the use of this gene profile would lead to a large number of patients
undergoing unnecessary treatment [15]. Mass-spectrometry based
proteomic methods have been applied to identify markers associated
with tumor aggressiveness and metastasis in oral cancer. Polachini et al.
found 155 differentially expressed proteins favoring metastasis [16].
More recently, a proteomic analysis by Harris et al. revealed 72 peptide
features associated with disease-specific death, metastasis and recur-
rence [17]. However, to our knowledge no proteomic profile with
predictive capability has been generated yet.
This work focuses on the processing and analysis of high-dimen-
sional MALDI-MSI data from TMAs to find biomarkers for head and
neck cancer. We describe the quality measures taken to avoid the in-
troduction of bias during data generation and data analysis, and we
assess the sensitivity of our classification approach. Finally, we test
whether we can predict lymph node metastasis from MALDI-MSI data of
head and neck cancer tumors.
2. Materials and methods
2.1. Patient samples
For this study, 240 patient samples were available: 212 cases of oral
squamous cell carcinoma (OSCC) and 28 cases of oropharyngeal squa-
mous cell carcinoma (OPSCC). These samples came from patients with
histologically proven oral or oropharyngeal squamous cell carcinoma
that underwent surgery between 1996 and 2005 at the University
Medical Center Utrecht in The Netherlands. Patients diagnosed with
synchronous primary tumors or previous malignancies in the head and
neck region were not included in this cohort [18].
In our study, we use two TMAs that contain tissue cores excised
from 120 patient samples. Per patient, three cores (0.6 mm in diameter)
of the central part of the primary tumor were present, see Fig. 1b. In
Table 1, the number of patients which showed lymph node metastasis is
listed. The two classes were randomly distributed across the TMAs. It is
important to have a random distribution of the samples across a TMA to
ensure the location of the samples on the TMA(s) is not a confounding
factor in the analysis.
2.2. Sample preparation
The TMAs contain formalin-fixed paraffin-embedded (FFPE) tissue.
This tissue is conserved by dehydration and cross-linking of the proteins
with formalin. After formalin fixation, the tissue is embedded in par-
affin to preserve tissue morphology and allow thin sectioning of the
tissue. FFPE tissue is widely used for clinical applications, due to easy
storage and handling.
The TMAs were prepared for MALDI-MSI analysis as previously
described in [19]. We summarize the important steps below. First, se-
rial 5 µm tick tissue sections were cut from the TMA blocks and
mounted onto conductive indium tin oxide (ITO) coated glass slides
(Delta Technologies, USA). Paraffin was removed using xylene washes
(twice, 5 min). Paraffin needs to be removed, as it causes ion suppres-
sion during mass spectrometric analysis.
The goal of the next steps in the sample preparation is to make the
proteins amenable to MSI analysis. First, rehydration is performed using
graded ethanol washes (100%, 100%, 95%, 75% and 30%, all 5 min)
and water washes (twice, 3 min). The used solvents were HPLC-grade.
Then, (part of) the cross-linking is reversed (most likely through heat-
induced hydrolysis [20]) by incubation of the sample in a buffer at high
temperature. The samples were incubated at 95 °C in a 10mM Tris
buffer pH 9 for 20min, and allowed to cool down to room temperature
before briefly rinsing them with water. Afterwards, the samples were
dried in a desiccator.
Trypsin was dissolved in 50mM ammoniumbicarbonate plus 25 µM
octylglucoside at a final concentration of 0.05 µg/µL. On-tissue diges-
tion was performed using a Suncollect automatic sprayer (SunChrom,
Germany). Eight layers were applied with a flow rate of 7.5 µL/min.
The quick movement of the localized spray over the tissue ensures that
the spatial information is retained. The samples were incubated at 37 °C
overnight in a humid environment (50% methanol in deionized water).
Fig. 1. Example of a head and neck cancer TMA. (a) Unprocessed MALDI-MSI spectrum from a tissue core. Inset: Hematoxylin and eosin (H&E) stained tissue core
with 80% tumor cells. (b) H&E stained TMA of 120 patients. (c) Selected ion image shows the distribution of a typical peptide peak.
Table 1
The patient samples used in this study.
Class description Yes No
Lymph node metastasis 134 106
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Proteins in FFPE tissue are typically digested with trypsin to free them
from remaining cross-links and aggregation which hinder their detec-
tion.
A matrix solution of 5mg/mL alpha-cyano-4-hydroxycinnamic acid
(CHCA) in 1:1 ACN:H2O with 0.1% trifluoroacetic acid was used.
Matrix was applied with the Suncollect sprayer. Eight successive coats
were applied with an increasing flow rate of 7.5–20 µL/min.
2.3. MALDI-MSI measurements
The experiments were performed with a MALDI-QTOF instrument
(Synapt G2Si HDMS, Waters, UK) in positive mode and an m/z range of
200–3500. Spectra were acquired with a stage step size of 100 µm and a
laser frequency of 1000 Hz (laser spot diameter 60 µm), with the
quadrupole set to have optimal transmission in the peptide region of the
mass spectrum. The instrument was operated in sensitivity mode during
all experiments, and on average 34 spatially resolved spectra were re-
corded for each core. Two data sets were acquired for each TMA; the
second set of samples was rotated 180 degrees during preparation and
measurement to avoid the introduction of bias.
MALDI-MSI spectra of FFPE tissue consist mainly of tryptic peptide
and matrix peaks. An exemplary unprocessed mass spectrum can be
found in Fig. 1a. MALDI-MSI studies of TMAs report the detection of
around 500 peptide peaks [21,22]. This is in line with our observation
of on average 700 tissue-related peaks per patient in the range of m/z
700–3500.
As was previously observed for FFPE tissue [23], the baseline of the
spectrum has a hill shape. This feature becomes more pronounced after
peak-picking of the spectra, see the next section and Fig. 2. The elevated
baseline is most likely caused by the rich mixture of molecules that is
desorbed and ionized from the digested tissue surface. Formalin fixa-
tion-induced adducts might further increase the number of different
ionized species [24]. Unresolved peaks lead to a loss in spectral re-
solution and a decrease in signal-to-noise ratio. A shorter digestion time
of two hours did not improve the quality of the spectra. Replacing the
Tris buffer (pH 9) with an acidic buffer (10mM citric acid at pH 6), as
was used in [25], did also not improve the signal-to-noise ratio.
2.4. Tissue core selection and pre-processing of the spectra
After MALDI-MSI analysis, the samples were washed with 100%
MeOH to remove the matrix and stained with hematoxylin and eosin (H
&E) using a standard protocol, see Fig. 1b. The percentage of tumor
cells per tissue core was determined by a dedicated head and neck
pathologist. Only tissue cores with more than 80% tumor cells were
used in this study. After this procedure there were still spectra from 122
patients, of which 74 were lymph node metastasis positive and 48
lymph node metastasis negative. Clinical follow-up data were available
for all 122 patients (Supplementary Information).
Spectra from the cores were extracted for data processing and
subsequent statistical analysis using an in-house developed MATLAB-
based software tool (The Mathworks, USA). This tool co-registers the
MSI data and the H&E scan of the same sample to accurately extract ‘on-
tissue’ spectra. The extracted spectra were subjected to peak detection
using the PEAPI algorithm [26].
Two data sets were acquired for each TMA; the second set of sam-
ples was rotated 180 degrees during preparation and measurement to
avoid the introduction of bias.
We tested the introduction of bias due to the location of the tissue
cores on the tissue microarray slides by measuring serial sections which
were rotated 180 degrees relative to the others during preparation and
measurement. We could not detect a significant influence of the loca-
tion on the data.
2.5. Data processing
For each patient, we have performed measurements on all available
tumor cores (maximum three), and for each core, spectra were obtained
at multiple locations or pixels. To reduce the variance in these mea-
surements, they are combined per patient by summation. Afterwards,
matrix-related peaks are removed, as illustrated by the purple dots in
Fig. 2. All peaks below m/z=700 are filtered out, because most of
them do not correspond to peptides. In the region of m/z 700–1500
peaks related to the matrix are located at the bottom of the spectrum,
see Fig. 2. To remove these peaks, the average patient spectrum is first
smoothed with a second order Savitzky-Golay filter, and then peaks that
lie below 75% of the smoothed average are removed. This Savitzky-
Golay filter has a width of 125 data points, corresponding to an m/z
range of 125. We then compute the average spectrum of all patients and
its baseline, again using a second order Savitzky-Golay filter with a
width of 125 data points. Note that 125 data points can now correspond
to a larger m/z range because some peaks have been removed. Peaks
that on average lie below the baseline are then removed from all patient
spectra.
Since the patient spectra have slightly different baselines, we per-
form baseline correction per patient. For each patient, we first estimate
the baseline with a median filter over a width of 125 data points. This
estimate of the baseline is still rather noisy, so we smooth it with a
second order Savitzky-Golay filter of the same width. For each patient,
the smoothed baseline is then subtracted from the data, as illustrated in
Fig. 3a. It is possible that some of the peaks lie below the baseline, so
that they have a negative intensity after this procedure. This poses no
problem for our classification approach, however. Finally, the baseline-
corrected spectra per patient are normalized by total intensity. Fig. 3b
shows examples of the resulting spectra for three randomly selected
patients between m/z=1000 and m/z= 1200. The processed spectra
are qualitatively quite similar, but note that some of the peaks show
significant differences between patients, which cannot be corrected for
through a single normalization constant.
We remark that it would often be better to perform per-patient
baseline correction and normalization before further data processing.
However, the procedure described above, in which matrix and low-in-
tensity peaks are first removed, gave us better qualitative agreement
between patient spectra.
2.6. Feature selection
There are several ways to select features (i.e. m/z values), see for
Fig. 2. Example of a peak-picked spectrum, obtained by combining data from
all tumor cores of the same patient. The m/z values indicated by purple dots are
filtered out during the pre-processing. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this
article.)
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example the discussion by Hilario et al. in Ref. [27]. Here we use
univariate feature selection, which means that the features are ranked
individually. We assume that class differences are expressed in a limited
number of features, for example no more than five or ten. Individual
features are then likely to show significant univariate differences. After
several features have been selected by a univariate approach, a suitable
classifier can combine them, potentially in a complex way.
We use two univariate statistical tests: the Wilcoxon rank-sum test
and the Kolmogorov-Smirnov test. These tests are performed on our
training data, which contains two classes, to estimate how (dis)similar
peaks are distributed in these classes. To select N features, the N peaks
with the smallest p-values are retained.
2.7. Classification
Different types of classifiers have their own strengths and weak-
nesses, depending on the data that they are applied to. Since we do not
know a priori what types of patterns will be present in our data, we use
three different classifiers, as implemented in the Scikit-Learn library
[28]:
• LDA: Linear Discriminant Analysis, which works well for linearly
separable data.
• NBC: Naive Bayes Classifier, which can work well for data in which
each single feature independently has (some) predictive power.
• DTC: Decision Tree Classifier, with a maximum depth of three. This
classifier can handle more complex relations between the features
by construction of a ‘decision tree’.
To test the performance of the different classifiers, we use so-called
k-fold cross-validation, with k=10. The data is randomly partitioned
into 10 subsamples of nearly equal size. Each subsample is once used
for testing, with the rest of the data used for feature selection and
training. Data from a patient is thus either used for testing or for
training, but never for both. After cross-validation, each patient has
been part of the test-group exactly once, so a full set of predicted class
labels is obtained. Then the number of true positives (TP), true nega-
tives (TN), false positives (FP) and false negatives (FN) is determined.
3. Results and discussion
3.1. Classification of lymph node metastasis
The performance of binary classifiers can be judged by different
metrics. Here we use a measure that can also be used when classes are
of unequal size, namely Matthews correlation coefficient (MCC), also
known as the φ coefficient:
=
−
+ + + +
MCC TPxTN FPxFN
TP FP TP FN TN FP TN FN( )( )( )( )
,where TP is the number of true positives etc. The MCC coefficient lies
between −1 and 1; these values indicate all predictions are wrong or
correct, respectively, whereas 0 indicates there is no predictive power.
If there are for example two equal size classes, for both of which 75% of
the predictions is correct, the MCC score is 0.5.
The prediction of lymph node metastasis using our workflow is
shown in Fig. 4. For Fig. 4a these features were selected using the
Wilcoxon rank-sum tests. The best results are obtained the decision tree
classifier in combination with one or two features, by far the most
important of which is m/z=718.4. This results in an MCC score of
about 0.4, and about 72% of the patients being classified correctly (TP,
FP, TN, FN=59 19 29 15). For reference, this corresponds to a sensi-
tivity of 80% and a specificity of 60%. This classification accuracy is
comparable to the results of [15] (72% negative predictive value),
which used a gene signature to predict lymph node metastasis.
For Fig. 4b the Kolmogorov-Smirnov test was used, and in combi-
nation with the decision tree classifier we also observe MCC scores of up
to about 0.4 and 72% correct classifications. The same tissue-derived
ion (m/z=718.4) is again responsible for almost all the predictive
power. The significance of a result is often expressed by the number of
standard deviations it corresponds to. As discussed below and shown in
Fig. 5, the standard deviation in the MCC scores is about 0.15 when
using randomized class labels, so that a score of 0.4 corresponds to
almost three standard deviations. In Fig. 6 samples from the two me-
tastasis classes are visualized using the m/z=718.4 feature. The pa-
tients with and without metastasis have a different distribution, al-
though there is also considerable overlap. MS/MS experiments might be
performed to identify the tissue-derived ion at m/z 718.4.
3.2. Sensitivity of method
To get an idea of the sensitivity of the classification approach, we
have performed tests with modified data. First, one representative peak
with an m/z value of 1325.7 was selected, which had an average in-
tensity. Then the class labels were randomized, after which the m/z
1325.7 peak was increased with a certain percentage in one of the
classes. This increase was performed after pre-processing, but before
feature selection. Then five features were selected using the
Kolmogorov-Smirnov test, after which the LDA classifier was applied
(we could also have used the naive Bayes or the decision tree classifier,
Fig. 3. (a) Example of a peak-picked spectrum with its baseline (black solid
curve). The spectrum after baseline subtraction is also shown (green spectrum).
(b) Examples of peak-picked spectra of three patients, after pre-processing,
zoomed in on the range m/z 1000–1200. Peak-picked spectra are shown as
continuous graphs for better readability. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this
article.)
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all work well for this type of artificial difference). Classification results
for different increases are shown in Fig. 5a, based on data from 40 runs
with randomized class labels. The error bars indicate the standard de-
viations in the MCC score, which are about 0.15. With an artificial in-
crease of 70%, the MCC score is about 0.3, which corresponds to two
standard deviations. Using the method and data presented here, we can
thus expect significant classification scores when the intensity of a
single peak differs by 70% between the classes. When multiple peaks
would show a similar increase, classification scores would drastically go
up, as long as the univariate differences are large enough for our feature
selection procedure. We remark that the above results with modified
data strongly depend on the signal to noise ratio of the spectra. When
Fig. 4. Classification results for lymph node metastasis (a, b). The left figures show results for feature selection with the Wilcoxon rank-sum test. The right figures
show results using the Kolmogorov-Smirnov test.
Fig. 5. (a) Test of the Kolmogorov-Smirnov feature selection method using
artificial data. A typical peptide peak at m/z 1325.7 has been increased by a
certain percentage in one of the classes. The error bars indicate plus and minus
one standard deviation. Data was collected from 40 runs with randomized class
labels. (b) Histogram of the peptide peak at m/z 1325.7 after preprocessing.
Fig. 6. (a) Box plot (whiskers at 1.5 times the interquartile range, with outliers
indicated) of the m/z 718.4 peak for patients with and without metastasis. (b) A
histogram of the m/z 718.4 peak for patients with and without metastasis.
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this ratio is high, peak intensities are large compared to their typical
fluctuations, making it easier to distinguish class differences from
random noise.
3.3. Tissue heterogeneity
A high signal to noise ratio of spectra and individual peaks is key for
the successful detection of biomarkers. A challenge in this regard is that
head and neck cancer tissue is quite heterogeneous: a small piece of a
single tumor may contain different types of tissue. MALDI-MSI can help
to overcome this, because it allows for histology-directed analysis. The
approach taken here was to include tissue cores based on their tumor
cell percentage, as determined by a dedicated head and neck patholo-
gist. This was done because we use relatively small cores with a dia-
meter of 0.6mm. In studies with larger tissue cores it is also possible to
select regions within a core, as done for example by Buck et al. for
metabolite imaging [29].
For the results presented in this paper we used tissue cores con-
taining at least 80% tumor cells. When we instead select tumors cores
containing at least 50% tumor cells, classification scores go drastically
down. The m/z 718.4 peak is still selected in the majority of cases, but
the best MCC scores are now below 0.1; much lower than the score of
0.4 found when using 80% tumor cells.
4. Conclusions
We have used MALDI-MSI data from head and neck cancer TMAs for
the purpose of biomarker prediction. A large and well-matched set of
tumors was used, which helps to compensate for the intrinsic hetero-
geneity of patient samples. The experimental methodology and the
preprocessing of the obtained spectra was described, as well as the
construction of a classifier for lymph node metastasis. We used two
univariate feature selection methods, three different classifiers, and
between one and ten features. The best results were obtained with a
decision tree classifier, and almost all the predictive power was based
on a single peak (m/z 718.4). We also demonstrated the sensitivity of
our classification method, using artificially modified data.
The primary assumption behind our approach is that class differ-
ences are expressed in a limited number of features/peaks, so that they
can be selected with a univariate test. Our approach is then a relatively
simple way to search for biomarkers in MALDI-MSI data. Afterwards,
independent validation of the found markers or patterns can be per-
formed with different samples and different analytical methods.
Acknowledgements
Part of this work belongs to the research programme of the
Netherlands Organisation for Scientific Research (NWO) and was per-
formed at the research institute AMOLF. RH acknowledges financial
support of the LINK program of the Dutch Province of Limburg. NM and
RH acknowledge financial support from the Dutch national program
COMMIT. RN acknowledges financial support from the Dutch Cancer
Society (research grant: 2014-6620). The authors thank Dr. Robert van
Es and the department of Head and Neck Surgical Oncology for pro-
viding the clinical data.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.ymeth.2018.04.004.
References
[1] S. Steurer, C. Borkowski, S. Odinga, M. Buchholz, C. Koop, H. Huland, M. Becker,
M. Witt, D. Trede, M. Omidi, O. Kraus, A.S. Bahar, A.S. Seddiqi, J.M. Singer,
M. Kwiatkowski, M. Trusch, R. Simon, M. Wurlitzer, S. Minner, T. Schlomm,
G. Sauter, H. Schlüter, MALDI mass spectrometric imaging based identification of
clinically relevant signals in prostate cancer using large-scale tissue microarrays,
Int. J. Cancer. 133 (2013) 920–928, http://dx.doi.org/10.1002/ijc.28080.
[2] W.M. Hardesty, M.C. Kelley, D. Mi, R.L. Low, R.M. Caprioli, Protein signatures for
survival and recurrence in metastatic melanoma, J. Proteomics 74 (2011)
1002–1014, http://dx.doi.org/10.1016/j.jprot.2011.04.013.
[3] B. Balluff, S. Rauser, S. Meding, M. Elsner, C. Schöne, A. Feuchtinger,
C. Schuhmacher, A. Novotny, U. Jtting, G. MacCarrone, H. Sarioglu, M. Ueffing,
H. Braselmann, H. Zitzelsberger, R.M. Schmid, H. Höfler, M.P. Ebert, A. Walch,
MALDI imaging identifies prognostic seven-protein signature of novel tissue mar-
kers in intestinal-type gastric cancer, Am. J. Pathol. 179 (2011) 2720–2729, http://
dx.doi.org/10.1016/j.ajpath.2011.08.032.
[4] S. Meding, B. Balluff, M. Elsner, C. Schöne, S. Rauser, U. Nitsche, M. Maak,
A. Schäfer, S.M. Hauck, M. Ueffing, R. Langer, H. Höfler, H. Friess, R. Rosenberg,
A. Walch, Tissue-based proteomics reveals FXYD3, S100A11 and GSTM3 as novel
markers for regional lymph node metastasis in colon cancer, J. Pathol. 228 (2012)
459–470, http://dx.doi.org/10.1002/path.4021.
[5] M. Nipp, M. Elsner, B. Balluff, S. Meding, H. Sarioglu, M. Ueffing, S. Rauser,
K. Unger, H. Höfler, A. Walch, H. Zitzelsberger, S100–A10, thioredoxin, and
S100–A6 as biomarkers of papillary thyroid carcinoma with lymph node metastasis
identified by MALDI Imaging, J. Mol. Med. 90 (2012) 163–174, http://dx.doi.org/
10.1007/s00109-011-0815-6.
[6] K. Yanagisawa, Y. Shyr, B.J. Xu, P.P. Massion, P.H. Larsen, B.C. White, J.R. Roberts,
M. Edgerton, A. Gonzalez, S. Nadaf, J.H. Moore, R.M. Caprioli, D.P. Carbone,
Proteomic patterns of tumour subsets in non-small-cell lung cancer, Lancet
(London, England) 362 (2003) 433–439, http://dx.doi.org/10.1016/S0140-
6736(03)14068-8.
[7] S.A. Schwartz, R.J. Weil, R.C. Thompson, Y. Shyr, J.H. Moore, S.A. Toms,
M.D. Johnson, R.M. Caprioli, Proteomic-based prognosis of brain tumor patients
using direct-tissue matrix-assisted laser desorption ionization mass spectrometry,
Cancer Res. 65 (2005) 7674–7681, http://dx.doi.org/10.1158/0008-5472.CAN-04-
3016.
[8] M. Elsner, S. Rauser, S. Maier, C. Schöne, B. Balluff, S. Meding, G. Jung, M. Nipp,
H. Sarioglu, G. Maccarrone, M. Aichler, A. Feuchtinger, R. Langer, U. Jütting,
M. Feith, B. Küster, M. Ueffing, H. Zitzelsberger, H. Höfler, A. Walch, MALDI
imaging mass spectrometry reveals COX7A2, TAGLN2 and S100–A10 as novel
prognostic markers in Barrett’s adenocarcinoma, J. Proteomics 75 (2012)
4693–4704, http://dx.doi.org/10.1016/j.jprot.2012.02.012.
[9] A. Quaas, A.S. Bahar, K. von Loga, A.S. Seddiqi, J.M. Singer, M. Omidi, O. Kraus,
M. Kwiatkowski, M. Trusch, S. Minner, E. Burandt, P. Stahl, W. Wilczak,
M. Wurlitzer, R. Simon, G. Sauter, A. Marx, H. Schlüter, MALDI imaging on large-
scale tissue microarrays identifies molecular features associated with tumour phe-
notype in oesophageal cancer, Histopathology 63 (2013) 455–462, http://dx.doi.
org/10.1111/his.12193.
[10] A. Hinsch, M. Buchholz, S. Odinga, C. Borkowski, C. Koop, J.R. Izbicki,
M. Wurlitzer, T. Krech, W. Wilczak, S. Steurer, F. Jacobsen, E.C. Burandt, P. Stahl,
R. Simon, G. Sauter, H. Schl??ter, MALDI imaging mass spectrometry reveals
multiple clinically relevant masses in colorectal cancer using large-scale tissue
microarrays, J. Mass Spectrom. 52 (2017) 165–173, http://dx.doi.org/10.1002/
jms.3916.
[11] S. Meding, U. Nitsche, B. Balluff, M. Elsner, S. Rauser, C. Schöne, M. Nipp, M. Maak,
M. Feith, M.P. Ebert, H. Friess, R. Langer, H. Höfler, H. Zitzelsberger, R. Rosenberg,
A. Walch, Tumor classification of six common cancer types based on proteomic
profiling by MALDI imaging, J. Proteome Res. 11 (2012) 1996–2003, http://dx.doi.
org/10.1021/pr200784p.
[12] A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, D. Forman, Global cancer sta-
tistics, CA Cancer J. Clin. 61 (2011) 69–90, http://dx.doi.org/10.3322/caac.20107.
[13] R. de Bree, R.P. Takes, J.A. Castelijns, J.E. Medina, S.J. Stoeckli, A.A. Mancuso,
J.L. Hunt, J.P. Rodrigo, A. Triantafyllou, A. Teymoortash, F.J. Civantos, A. Rinaldo,
K.T. Pitman, M. Hamoir, K.T. Robbins, C.E. Silver, O.S. Hoekstra, A. Ferlito,
Advances in diagnostic modalities to detect occult lymph node metastases in head
and neck squamous cell carcinoma, Head Neck 37 (2015) 1829–1839, http://dx.
doi.org/10.1002/hed.23814.
[14] A. Teymoortash, S. Hoch, B. Eivazi, J.A. Werner, Postoperative morbidity after
different types of selective neck dissection, Laryngoscope 120 (2010), http://dx.doi.
org/10.1002/lary.20894.
[15] S.R. Van Hooff, F.K.J. Leusink, P. Roepman, R.J. Baatenburg De Jong, E.J.M. Speel,
M.W.M. Van Den Brekel, M.L.F. Van Velthuysen, P.J. Van Diest, R.J.J. Van Es,
M.A.W. Merkx, J.A. Kummer, C.R. Leemans, E. Schuuring, J.A. Langendijk,
M. Lacko, M.J. De Herdt, J.C. Jansen, R.H. Brakenhoff, P.J. Slootweg, R.P. Takes,
F.C.P. Holstege, Validation of a gene expression signature for assessment of lymph
node metastasis in oral squamous cell carcinoma, J. Clin. Oncol. 30 (2012)
4104–4110, http://dx.doi.org/10.1200/JCO.2011.40.4509.
[16] G.M. Polachini, L.M. Sobral, A.M.C. Mercante, A.F. Paes-Leme, F.C.A. Xavier,
T. Henrique, D.M. Guimarães, A. Vidotto, E.E. Fukuyama, J.F. Góis-Filho,
P.M. Cury, O.A. Curioni, P. Michaluart, A.M.A. Silva, V. Wünsch-Filho, F.D. Nunes,
A.M. Leopoldino, E.H. Tajara, Proteomic approaches identify members of cofilin
pathway involved in oral tumorigenesis, PLoS One 7 (2012) 1–13, http://dx.doi.
org/10.1371/journal.pone.0050517.
[17] T.M. Harris, P. Du, N. Kawachi, T.J. Belbin, Y. Wang, N.F. Schlecht, T.J. Ow,
C.E. Keller, G.J. Childs, R.V. Smith, R.H. Angeletti, M.B. Prystowsky, J. Lim,
Proteomic analysis of oral cavity squamous cell carcinoma specimens identifies
patient outcome-associated proteins, Arch. Pathol. Lab. Med. 139 (2015) 494–507,
http://dx.doi.org/10.5858/arpa.2014-0131-OA.
[18] T.J.W. Klein Nulent, P.J. Van Diest, P. Van Der Groep, F.K.J. Leusink,
C.L.J.J. Kruitwagen, R. Koole, E.M. Van Cann, Cannabinoid receptor-2
N.E. Mascini et al. Methods xxx (xxxx) xxx–xxx
6
immunoreactivity is associated with survival in squamous cell carcinoma of the
head and neck, Br. J. Oral Maxillofac. Surg. 51 (2013) 604–609, http://dx.doi.org/
10.1016/j.bjoms.2013.03.015.
[19] R. Casadonte, R.M. Caprioli, Proteomic analysis of formalin-fixed paraffin-em-
bedded tissue by MALDI imaging mass spectrometry, Nat. Protoc. 6 (2011)
1695–1709, http://dx.doi.org/10.1038/nprot.2011.388.
[20] S. Magdeldin, T. Yamamoto, Toward deciphering proteomes of formalin-fixed
paraffin-embedded (FFPE) tissues, Proteomics. 12 (2012) 1045–1058, http://dx.
doi.org/10.1002/pmic.201100550.
[21] M.-C. Djidja, E. Claude, M.F. Snel, S. Francese, P. Scriven, V. Carolan, M.R. Clench,
Novel molecular tumour classification using MALDI-mass spectrometry imaging of
tissue micro-array, Anal. Bioanal. Chem. 397 (2010) 587–601, http://dx.doi.org/
10.1007/s00216-010-3554-6.
[22] T.M. Morgan, E.H. Seeley, O. Fadare, R.M. Caprioli, P.E. Clark, Imaging the clear
cell renal cell carcinoma proteome, J. Urol. 189 (2013) 1097–1103, http://dx.doi.
org/10.1016/j.juro.2012.09.074.
[23] R. Lemaire, A. Desmons, J.C. Tabet, R. Day, M. Salzet, I. Fournier, Direct analysis
and MALDI imaging of formalin-fixed, Paraffin-Embedded Tissue Sections (2007),
http://dx.doi.org/10.1021/PR060549I.
[24] Virginie Redeker, Jean-Yves Toullec, Joëlle Vinh, Jean Rossier, D. Soyez,
Combination of peptide profiling by matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry and immunodetection on single glands or cells,
Anal. Chem. (1998), http://dx.doi.org/10.1021/AC971309C.
[25] J.O.R. Gustafsson, M.K. Oehler, S.R. McColl, P. Hoffmann, Citric Acid Antigen
Retrieval (CAAR) for tryptic peptide imaging directly on archived formalin-fixed
paraffin-embedded tissue, J. Proteome Res. 9 (2010) 4315–4328, http://dx.doi.org/
10.1021/pr9011766.
[26] G.B. Eijkel, B.K. Kaletaş, I.M. Van Der Wiel, J.M. Kros, T.M. Luider, R.M.A. Heeren,
Correlating MALDI and SIMS imaging mass spectrometric datasets of biological
tissue surfaces, Surf. Interface Anal. 41 (2009) 675–685, http://dx.doi.org/10.
1002/sia.3088.
[27] M. Hilario, A. Kalousis, C. Pellegrini, M. Müller, Processing and classification of
protein mass spectra, Mass Spectrom. Rev. 25 (2006) 409–449, http://dx.doi.org/
10.1002/mas.20072.
[28] F. Pedregosa, G. Varoquaux, A. Gramfort, V. Michel, B. Thirion, O. Grisel, M.
Blondel, P. Prettenhofer, R. Weiss, V. Dubourg, J. Vanderplas, A. Passos, D.
Cournapeau, M. Brucher, M. Perrot, É. Duchesnay, Journal of machine learning
research : JMLR., MIT Press, 2001. http://dl.acm.org/citation.cfm?id=2078195.
[29] A. Buck, B. Balluff, A. Voss, R. Langer, H. Zitzelsberger, M. Aichler, A. Walch, How
suitable is matrix-assisted laser desorption/ionization-time-of-flight for metabolite
imaging from clinical formalin-fixed and paraffin-embedded tissue samples in
comparison to matrix-assisted laser desorption/ionization-fourier transform ion
cyclotro, Anal. Chem. 88 (2016) 5281–5289, http://dx.doi.org/10.1021/acs.
analchem.6b00460.
N.E. Mascini et al. Methods xxx (xxxx) xxx–xxx
7
